-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Statera Biopharma, Inc. (NASDAQ:STAB) Short Interest Up 444.2% in October
Statera Biopharma, Inc. (NASDAQ:STAB) Short Interest Up 444.2% in October
Statera Biopharma, Inc. (NASDAQ:STAB – Get Rating) was the target of a large increase in short interest in the month of October. As of October 15th, there was short interest totalling 2,390,000 shares, an increase of 444.2% from the September 30th total of 439,200 shares. Currently, 5.8% of the shares of the stock are sold short. Based on an average daily volume of 2,740,000 shares, the days-to-cover ratio is currently 0.9 days.
Statera Biopharma Stock Performance
STAB remained flat at $0.15 during midday trading on Friday. 516,431 shares of the company's stock were exchanged, compared to its average volume of 3,652,617. Statera Biopharma has a one year low of $0.11 and a one year high of $4.18. The company's fifty day moving average price is $0.17 and its 200-day moving average price is $0.22.
Get Statera Biopharma alerts:Institutional Trading of Statera Biopharma
Large investors have recently modified their holdings of the business. Raymond James Financial Services Advisors Inc. grew its position in shares of Statera Biopharma by 275.9% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 112,250 shares of the company's stock valued at $35,000 after purchasing an additional 82,391 shares during the last quarter. UBS Group AG acquired a new stake in shares of Statera Biopharma in the first quarter valued at approximately $37,000. Virtu Financial LLC grew its position in shares of Statera Biopharma by 409.2% in the first quarter. Virtu Financial LLC now owns 157,678 shares of the company's stock valued at $50,000 after purchasing an additional 126,715 shares during the last quarter. Northern Trust Corp grew its position in shares of Statera Biopharma by 335.9% in the first quarter. Northern Trust Corp now owns 171,110 shares of the company's stock valued at $54,000 after purchasing an additional 131,855 shares during the last quarter. Finally, Empery Asset Management LP purchased a new position in shares of Statera Biopharma during the first quarter valued at approximately $105,000. 8.40% of the stock is currently owned by institutional investors and hedge funds.
Statera Biopharma Company Profile
(Get Rating)Statera BioPharma, Inc, a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers.
Featured Stories
- Get a free copy of the StockNews.com research report on Statera Biopharma (STAB)
- McDonald's Stock Sizzles, but Will it Hit a New All-Time High?
- Chevron Gushes More Profits; Is it Time for Investors to Buy?
- Can Comcast Monetize Existing Users for Streaming Success?
- Why is Amazon Stock Falling? Is the Sell-Off Overdone?
- Apple Inc. Stock Q4 Results Beat Negative Outlook, Stock Rises
Receive News & Ratings for Statera Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Statera Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
Statera Biopharma, Inc. (NASDAQ:STAB – Get Rating) was the target of a large increase in short interest in the month of October. As of October 15th, there was short interest totalling 2,390,000 shares, an increase of 444.2% from the September 30th total of 439,200 shares. Currently, 5.8% of the shares of the stock are sold short. Based on an average daily volume of 2,740,000 shares, the days-to-cover ratio is currently 0.9 days.
斯塔特拉生物製藥公司 (NASDAQ: STAB — 獲取評級) 是在十月份短期利益大幅增加的目標.截至十月十五日,共有 2,39 萬股短期權益,較九月三十日共 439,200 股股份增加了 444.2%。目前,該股票的 5.8% 的股份賣空。根據每日平均交易量 2,740,000 股,目前的日數佔覆蓋率為 0.9 天。
Statera Biopharma Stock Performance
斯泰拉生物製藥股票表現
STAB remained flat at $0.15 during midday trading on Friday. 516,431 shares of the company's stock were exchanged, compared to its average volume of 3,652,617. Statera Biopharma has a one year low of $0.11 and a one year high of $4.18. The company's fifty day moving average price is $0.17 and its 200-day moving average price is $0.22.
在周五中午交易期間,STAB 保持平穩 0.15 美元。該公司股票的交易量為 516,431 股,而其平均交易量為 3,652,617。斯泰拉生物製藥的一年低點為 0.11 美元,一年高點為 4.18 美元。該公司的五十天移動平均價為 0.17 美元,其 200 天移動平均價格為 0.22 美元。
Institutional Trading of Statera Biopharma
斯泰拉生物製藥的機構交易
Large investors have recently modified their holdings of the business. Raymond James Financial Services Advisors Inc. grew its position in shares of Statera Biopharma by 275.9% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 112,250 shares of the company's stock valued at $35,000 after purchasing an additional 82,391 shares during the last quarter. UBS Group AG acquired a new stake in shares of Statera Biopharma in the first quarter valued at approximately $37,000. Virtu Financial LLC grew its position in shares of Statera Biopharma by 409.2% in the first quarter. Virtu Financial LLC now owns 157,678 shares of the company's stock valued at $50,000 after purchasing an additional 126,715 shares during the last quarter. Northern Trust Corp grew its position in shares of Statera Biopharma by 335.9% in the first quarter. Northern Trust Corp now owns 171,110 shares of the company's stock valued at $54,000 after purchasing an additional 131,855 shares during the last quarter. Finally, Empery Asset Management LP purchased a new position in shares of Statera Biopharma during the first quarter valued at approximately $105,000. 8.40% of the stock is currently owned by institutional investors and hedge funds.
大型投資者最近修改了他們對業務的持有量。雷蒙德詹姆斯金融服務顧問公司在斯塔拉生物製藥股份的地位 275.9% 在第一季度.雷蒙詹姆斯金融服務顧問公司在上一季度額外購買 82,391 股股票後,現在擁有該公司股票的 112,250 股價值 35,000 美元。瑞銀集團股份公司在第一季度收購了 Statera 生物製藥股份的新股份,價值約為 37,000 美元。Virtu 金融有限責任公司在第一季度增長了其在斯塔特拉生物製藥股份的地位 409.2%。在上一季度額外購買 126,715 股股票後,維圖金融有限責任公司現在擁有該公司 157,678 股價值 50,000 美元的股票。北方信託公司在第一季度增長了 335.9% 在斯塔特拉生物製藥的股份中的地位。北方信託公司在上一季度額外購買 131,855 股股票後,現在擁有該公司 171,110 股股票,價值為 54,000 美元。最後,英皇資產管理有限公司在第一季度購買了 Statera 生物製藥股份的新頭寸,價值約為 105,000 美元。目前,該股票的 8.40% 由機構投資者和對沖基金擁有。
Statera Biopharma Company Profile
斯泰拉生物製藥公司簡介
Statera BioPharma, Inc, a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers.
Statera BioHharma, Inc 是一家臨床階段生物製藥公司,以專有平台為重新平衡人體免疫系統和恢復平衡體內的免疫系統和恢復穩態,開發針對自身免疫、中性粒細胞減少/貧血、新興病毒和癌症的新型免疫療法。該公司正在開發旨在直接引起患者內部抗原特異性殺傷 T 細胞和抗體的反應的療法,從而激活針對自身免疫性,炎症,傳染性疾病和癌症的必要免疫防禦能力。
Featured Stories
特色故事
- Get a free copy of the StockNews.com research report on Statera Biopharma (STAB)
- McDonald's Stock Sizzles, but Will it Hit a New All-Time High?
- Chevron Gushes More Profits; Is it Time for Investors to Buy?
- Can Comcast Monetize Existing Users for Streaming Success?
- Why is Amazon Stock Falling? Is the Sell-Off Overdone?
- Apple Inc. Stock Q4 Results Beat Negative Outlook, Stock Rises
- 獲取有關斯泰拉生物製藥(STAB)的研究報告的免費副本
- 麥當勞股票嘶嘶聲,但它會創下歷史新高嗎?
- 雪佛龍湧出更多利潤;投資者是時候購買了嗎?
- 康卡斯特可以通過現有用戶獲利以獲得流媒體成功嗎?
- 為什麼是亞馬遜股票下跌?拋售是否過度?
- 蘋果公司第四季度股票結果擊敗負面前景,股市上漲
Receive News & Ratings for Statera Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Statera Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
接收斯泰拉生物製藥日報的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Statera 生物製藥及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧